http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 30 Mar 2026 16:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792 http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LS/ca.qc" idsrc="xmltag.org" >QUÉBEC</location></span>, <span class="legendSpanClass"><chron>March 30, 2026</chron></span> /PRNewswire/ - <span value="TorontoVE:GSD" idsrc="xmltag.org" >Devonian Health Group Inc.</span> ("<b>Devonian</b>" or the "<b>Company</b>") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today highlights the results of its annual general and special meeting of shareholders held on <chron>March 27, 2026</chron> (the "<b>Meeting</b>") online via live webcast. The Company reported that shareholders voted on, and approved, the following proposals at the Meeting.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/PRNewswire/Devonian+Reports+Results+of+its+Annual+General+and+Special+Meeting+of+Shareholders/26240404.html Mon, 30 Mar 2026 16:00:00 -0400 A.05344465 A.20001523 A.30400265 A.36078215 A.50216650 DVHGF GSD O.02395703 O.02555813 O.02686980 O.47005133 O.49066140 O.57132792